German Sanz
Overview
Explore the profile of German Sanz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
48
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Campos H, Pereira R, de Oliveira Ferreira P, Uchenna N, Branco da Silva C, Pruccoli L, et al.
Chem Biol Interact
. 2024 Apr;
395:111026.
PMID: 38679115
In the pursuit of novel antioxidant therapies for the prevention and treatment of neurodegenerative diseases, three new arylpiperazine derivatives (LQFM181, LQFM276, and LQFM277) were synthesized through a molecular hybridization approach...
2.
de Oliveira L, Florentino I, Silva D, Pazini F, de Carvalho F, Sanz G, et al.
Can J Physiol Pharmacol
. 2023 Mar;
101(5):216-225.
PMID: 36866837
Molecular modification of compounds remains important strategy towards the discovery of new drugs. In this sense, this study presents a new pyrazole derivative 5-(1-(2-fluorophenyl)-1-pyrazol-4-yl)-1-tetrazole (LQFM039) and evaluated the anti-inflammatory, analgesic, ...
3.
Machado A, de Carvalho F, Mouraa R, Chaves L, Liao L, Sanz G, et al.
Curr Org Synth
. 2021 Dec;
18(8):844-853.
PMID: 34886771
Background: Privileged scaffolds are of high importance for molecules containing the pyrazole subunit due to their broad spectrum of pharmacological activities. For this reason, a method that is more efficient...
4.
Almeida L, Santana I, Moreira L, Turones L, Sanz G, Vaz B, et al.
CNS Neurol Disord Drug Targets
. 2021 Nov;
21(6):520-532.
PMID: 34781873
Background: Pharmacological treatments for mental disorders, such as anxiety and depression, present several limitations and adverse effects. Therefore, new pharmacotherapy with anxiolytic and antidepressant potential is necessary, and the study...
5.
Moreira L, Silva R, da Silva D, Mendes M, Brito A, de Carvalho F, et al.
Behav Brain Res
. 2021 Sep;
417:113582.
PMID: 34536431
The current treatments available for anxiety and depression are only palliative. Full remission has remained elusive, characterizing unmet medical needs. In the scope of an academic drug discovery program, we...
6.
Galvao G, Florentino I, Sanz G, Vaz B, Liao L, Sabino J, et al.
Int Immunopharmacol
. 2020 Sep;
88:106893.
PMID: 32892073
LQFM219 is a molecule designed from celecoxibe (COX-2 inhibitor) and darbufelone (inhibitor of COX-2 and 5-LOX) lead compounds through a molecular hybridisation strategy. Therefore, this work aimed to investigate the...
7.
Almeida D, da Silva D, Moreira L, Menegatti R, Liao L, Sanz G, et al.
Eur J Pharmacol
. 2020 Aug;
886:173388.
PMID: 32768504
The aim of this study was to synthesise the novel di-tert-butylphenol compound, 5-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-thioxo-dihydropyrimidine-4,6(1H, 5H)-dione (LQFM218), and evaluate the potential anti-nociceptive and anti-inflammatory activities in acute (mice) models in vivo. The...
8.
Moreira L, Brito A, Fontana C, de Carvalho F, Sanz G, Vaz B, et al.
Behav Brain Res
. 2020 Jul;
394:112827.
PMID: 32730857
Piperazine derivatives are an attractive class of chemical compounds for the treatment of various mental illness. Herein, we demonstrated the synthesis of LQFM212, a piperazine derivative, behavioral evaluation in mice...
9.
Oliveria J, Silva D, Florentino I, da Silva L, Sanz G, Vaz B, et al.
Inflammopharmacology
. 2020 Jun;
28(4):915-928.
PMID: 32529601
Aims: This study investigated the antinociceptive and anti-inflammatory effects of new pyrazole compounds LQFM011(5), LQFM043(6) and LQFM044(7) as well as the mechanisms of action and acute in vitro toxicity. Main...
10.
da Silva A, Dos Santos Rodrigues B, Andrade W, Marques Dos Santos T, de Carvalho F, Sanz G, et al.
Chem Biol Interact
. 2020 May;
325:109127.
PMID: 32437695
Inhibition of mouse double minute 2 homolog (MDM2)-p53 interaction and reactivation of p53 signaling have been explored as effective anticancer therapeutic strategy. The potent and specific antitumor activity shown by...